About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Effects of ONO-2506PO in Patients With Alzheimer's Disease

Effects of ONO-2506PO in Patients With Alzheimer's Disease

NCT00083421·87 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Ono Pharma USA Inc

Age

50–90

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
Standardized MMSE Score of 13 to 24 points (inclusive)
Modified Hachinski score equal or less than 4

You may not be if

Serious systemic disease that may preclude survival to study completion
Other illnesses that may include dementive features

The record

StatusCompleted

PhasePhase 2

Taking part647

StartedJun 2004

UpdatedJun 13, 2012

Conditions

Alzheimer's Disease

Where87

Kirkland Clinic
Birmingham, Alabama, United States
Alzheimers Disease Research Center
Birmingham, Alabama, United States
Pivotal Research Center
Mesa, Arizona, United States